Production of stem cell factor in canine mast cell tumors

Yosuke Amagai; Akane Tanaka; Kyungsook Jung; Akira Matsuda; Kumiko Oida; Sho Nishikawa; Hyosun Jang; Saori Ishizaka; Hiroshi Matsuda

doi:10.1016/j.rvsc.2013.10.014

Production of stem cell factor in canine mast cell tumors

Res Vet Sci. 2014 Feb;96(1):124-6. doi: 10.1016/j.rvsc.2013.10.014. Epub 2013 Nov 7.

Authors

Yosuke Amagai¹, Akane Tanaka², Kyungsook Jung¹, Akira Matsuda³, Kumiko Oida¹, Sho Nishikawa¹, Hyosun Jang¹, Saori Ishizaka¹, Hiroshi Matsuda⁴

Affiliations

¹ Cooperative Major in Advanced Health Science, Graduate School of Bio-Applications and System Engineering, Tokyo University of Agriculture and Technology, Tokyo, Japan.
² Cooperative Major in Advanced Health Science, Graduate School of Bio-Applications and System Engineering, Tokyo University of Agriculture and Technology, Tokyo, Japan; Laboratories of Comparative Animal Medicine, Division of Animal Life Science, Tokyo University of Agriculture and Technology, Tokyo, Japan. Electronic address: akane@cc.tuat.ac.jp.
³ Laboratories of Veterinary Molecular Pathology and Therapeutics, Division of Animal Life Science, Tokyo University of Agriculture and Technology, Tokyo, Japan.
⁴ Cooperative Major in Advanced Health Science, Graduate School of Bio-Applications and System Engineering, Tokyo University of Agriculture and Technology, Tokyo, Japan; Laboratories of Veterinary Molecular Pathology and Therapeutics, Division of Animal Life Science, Tokyo University of Agriculture and Technology, Tokyo, Japan.

PMID: 24269079
DOI: 10.1016/j.rvsc.2013.10.014

Abstract

Mast cell tumor (MCT) is the most common cutaneous tumor in dogs. We recently revealed that production of stem cell factor (SCF) contributes to the proliferation of neoplastic mast cells in an autocrine/paracrine manner. The aim of the present study was to determine the contribution of the mechanism in clinical MCTs. In consequence, high SCF expression (>10 times compared to HRMC cells) was observed in 5 of 7 MCT samples used in the study regardless of KIT mutation, which was confirmed in immunohistochemical analysis. In addition, production of SCF was observed in Ki-67-positive cells in the MCT xenograft. These results indicate the broad contribution of SCF autocrine/paracrine mechanism on clinical MCTs, providing the rationale for the clinical use of KIT inhibitors regardless of KIT mutation.

Keywords: KIT; Mast cell tumor; Stem cell factor.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Dog Diseases / genetics
Dog Diseases / metabolism*
Dogs
Female
Flow Cytometry
Immunohistochemistry / veterinary
Mast Cells / metabolism*
Mice
Mice, Inbred BALB C
Mice, Nude
RNA, Neoplasm / chemistry
RNA, Neoplasm / genetics
Real-Time Polymerase Chain Reaction / veterinary
Skin Neoplasms / genetics
Skin Neoplasms / metabolism*
Stem Cell Factor / genetics
Stem Cell Factor / metabolism*

Substances

RNA, Neoplasm
Stem Cell Factor